Entrada Therapeutics (TRDA) Amortizatization of Intangibles (2022 - 2026)

Entrada Therapeutics' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $548000.0 for Q1 2026.

• On a quarterly basis, Amortizatization of Intangibles fell 59.04% year-over-year to $548000.0 in Q1 2026; TTM through Mar 2026 was $2.9 million, a 69.08% decrease from a year earlier, with the FY2025 full-year figure at $3.7 million, down 63.36% from the prior year.
• Amortizatization of Intangibles slipped to $548000.0 in Q1 2026 per TRDA's latest filing, from $633000.0 in the prior quarter.
• Across five years, Amortizatization of Intangibles topped out at $3.2 million in Q3 2024 and bottomed at -$145000.0 in Q2 2022.
• The 5-year median for Amortizatization of Intangibles is $961000.0 (2025), against an average of $1.2 million.
• Across the five-year window, Amortizatization of Intangibles jumped 5687.5% in 2023 and plunged 77.0% in 2025, its largest moves.
• Year by year, Amortizatization of Intangibles stood at $104000.0 in 2022, then soared by 1822.12% to $2.0 million in 2023, then advanced by 25.41% to $2.5 million in 2024, then plunged by 74.75% to $633000.0 in 2025, then declined by 13.43% to $548000.0 in 2026.
• Per Business Quant, the three latest TRDA Amortizatization of Intangibles figures stand at $548000.0 (Q1 2026), $633000.0 (Q4 2025), and $739000.0 (Q3 2025).